This synergy of rapid onset combined with sustained release, integrating PPARα-mediated hepatic metabolic regulation with BRP-induced microecological remodeling, may substantially enhance therapeutic efficacy against MASLD. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.